FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

CIPLA Share Price Discussion

Cipla Ltd.
NSE: CIPLA | BSE: 500087 | ISIN: INE059A01026 | Sector: Pharmaceuticals and health care

CIPLA Rating

3.8/5 (16 Ratings)
CIPLA Share Price *
435.75 -11.75 (-2.63%)
* (quote may be delayed)
Find answers to all your questions on live CIPLA message board: Is CIPLA buy or sell? Should I buy CIPLA shares? Why are CIPLA shares falling? Should I invest in CIPLA stock?

You can also check CIPLA share price target recommended by brokerages.

CIPLA Discussion Forum

@sagaani • Reputation: -16,172

2 ND TARGET DONE
SELL CIPLA 446.3 TARGET 441.55_436_431 STOPLOSS 450 SAFE TRADERS CAN EXIT AT 448.15
FROM 446.3 TO 436 GIVING RS. 10.3 PER SHARE PROFIT
HAPPY TRADING
Like
reply
Reply
@newsbot • Reputation: 2,308
Gujarat Gas, Britannia among 10 stocks which brokerages have upgraded to 'buy'
Gujarat Gas, Cipla among 10 stocks which brokerages have upgraded to 'buy'
Moneycontrol
Like
reply
Reply
@sriharinune • Reputation: 5,824
CIPLA

Type
Buy
Instrument
CIPLA
Entry Price
₹447
Price@Trade
₹441.85
Target Price
₹457
Stop Price
₹444
Valid Till
Feb 20, 2020 3:20 PM
Status
Expired before entry
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 20 8:50 PM

Update
Expired before entry
Price @ Update
₹435.5
@sagaani • Reputation: -16,172

SELL CIPLA 446.3 TARGET 441.55_436_431 STOPLOSS 450 SAFE TRADERS CAN EXIT AT 448.15
Like
reply
Reply
@moving • Reputation: 0

CIPLA - chart - 611613

Like
reply
Reply
@sagaani • Reputation: -16,172

SELL CIPLA BELOW 435.75 TARGET 431_426_421 STOPLOSS 440 SAFE TRADERS CAN EXIT AT 437.95
Like
reply
Reply
@TTA • Reputation: 23,829
CIPLA MAR20 FUT

Type
Buy
Instrument
CIPLA MAR20 FUT
Entry Price
₹434
Price@Trade
₹434
Target Price
₹444.9
Stop Price
₹424.9
Valid Till
Mar 26, 2020 3:20 PM
Margin
₹88,566.37 approx for 1150 Qty
Status
Target Achieved
Exit Price
₹444.9
Net P&L
14.15% Profit
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 19 5:15 PM

Update
Target Achieved
Exit Price
₹444.9
JACKPOT FNO CALL in CIPLA
BUY CIPLA FUTURE@433.50 SL 2 TARGET 438

NEW HIGH 435.40
RS 2200 PROFIT
Like
reply
Reply

BUY CIPLA FUTURE@433.50 SL 2 TARGET 438
Like
reply
Reply
@newsbot • Reputation: 2,308
Hot Stocks: 'Use rally in PSU bank and auto stocks to create fresh shorts'
We advise focusing on defensives such as IT, Pharma and FMCG and select private banking majors for long trades
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Market Headstart: Nifty likely to consolidate further; avoid long positions for now
The index closed below 12,050 levels and formed bearish candle for the third straight session as closing was lower than opening value.
Moneycontrol
Like
reply
Reply

#cipla is good to short below 444 for 441, 437 close below this for 433, 431 & 427, buy only above 449.
Like
reply
Reply
@newsbot • Reputation: 2,308
Will the Wockhardt move help Dr Reddy's break into the big league?
Analysts say unlike previous attempts, Dr Reddy’s is making more concerted effort to expand in India
Moneycontrol
Like
reply
Reply
@rajivkumarjha • Reputation: -176,273
CIPLA FEB20 450 CE

Type
Buy
Instrument
CIPLA FEB20 450 CE
Entry Price
₹7.45
Price@Trade
₹7.45
Target Price
₹20
Stop Price
₹5.4
Valid Till
Feb 24, 2020 3:20 PM
Margin
₹8,567.5 approx for 1150 Qty
Status
Stoploss Hit
Exit Price
₹5.4
Net P&L
-27.52% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 17 2:51 PM

Update
Stoploss Hit
Exit Price
₹5.4
@100billionclub • Reputation: 3,727
CIPLA FEB20 FUT

Type
Sell
Instrument
CIPLA FEB20 FUT
Entry Price
₹445.5
Price@Trade
₹445
Target Price
₹440
Stop Price
₹449.5
Valid Till
Feb 13, 2020 3:20 PM
Margin
₹90,654.05 approx for 1150 Qty
Status
Stoploss Hit
Exit Price
₹449.5
Net P&L
-5.07% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 13 4:42 PM

Update
Trade Entered
Entry Price
₹445.5
TrackerBot @trackerbot
Feb 13 6:51 PM

Update
Stoploss Hit
Exit Price
₹449.5
@100billionclub • Reputation: 3,727
CIPLA FEB20 FUT

Type
Buy
Instrument
CIPLA FEB20 FUT
Entry Price
₹449
Price@Trade
₹448.8
Target Price
₹456
Stop Price
₹444
Valid Till
Feb 19, 2020 3:20 PM
Margin
₹91,282.42 approx for 1150 Qty
Status
Exited
Exit Price
₹445.65
Net P&L
-4.22% Loss
Like
reply
Reply (3)
Latest replies
TrackerBot @trackerbot
Feb 12 6:47 PM

Update
Trade Entered
Entry Price
₹449
Billion Club @100billionclub
Feb 13 3:15 PM

Update
Exited
Exit Price
₹445.65
Net P&L
-4.22% Loss
Billion Club @100billionclub
Feb 13 3:15 PM

CARRIED: ONCE EXIT LONG IN CIPLA AT 445.70. BOOK LOSS RS. 3,795
@newsbot • Reputation: 2,308
Indian drug companies get enquries on supplies of anti-HIV drugs for Coronavirus treatment
China's National Health Commission is repurposing the antiretroviral combination of Lopinavir and Ritonavir, which is meant to treat HIV, as a possible treatment for the symptoms of the coronavirus.
Moneycontrol
Like
reply
Reply
@sagaani • Reputation: -16,172

CIPLA - chart - 594717
BUY CIPLA 446 TARGET 451_456_462 STOPLOSS 442 SAFE TRADERS CAN EXIT AT 444.05
1 st target done - happy trading
Like
reply
Reply
@newsbot • Reputation: 2,308
Hold Cipla; target of Rs 490: ICICI Direct
ICICI Direct recommended hold rating on Cipla with a target price of Rs 490 in its research report dated February 07, 2019.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Cipla share price rises on distribution agreement for antipsychotic drug
The transaction allows Cipla Medpro to market and distribute the Medicine in South Africa and neighbouring countries.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Stocks in the news: ITC, Cipla, Oil India, Petronet LNG, Kalpataru Power, Punjab & Sind Bank
Avenue Supermarts | Petronet LNG | NALCo | Cipla | Nelcast and Bombay Dyeing are stocks, which are in news today.
Moneycontrol
Like
reply
Reply
Buy Cipla target of Rs 540: Sharekhan
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 540 in its research report dated February 05, 2019.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Buy Cipla target of Rs 540: Sharekhan
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 540 in its research report dated February 05, 2019.
Moneycontrol
Like
reply
Reply
@stocktrendr • Reputation: 319

Cipla expands women’s health portfolio through acquisition of 4 key brands from Wanbury
Like
reply
Reply
@newsbot • Reputation: 2,308
Stocks in the news: ACC, M&M, Yes Bank, Tata Steel, Britannia, Cipla, Om Metals, MGL
Oberoi Realty | ACC | J&K Bank | Om Metals and Bharat Forge are stocks, which are in news today.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Trade Setup for Monday: Top 15 things to know before Opening Bell
Experts feel that there could be a possibility of further downside if Nifty50 trades below 12,160 levels in the coming week as well. The near term outlook is tilted towards bears as MACD gave a bearish crossover or triggered a sell signal on charts.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
With Budget behind, brokerages cut target price on 5 stocks post Q3 results
Monetary Policy Committee (MPC) of Reserve Bank of India (RBI) has kept the repo rate under the liquidity adjustment facility (LAF) unchanged at 5.15 percent.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Cipla Standalone December 2019 Net Sales at Rs 2,926.20 crore, up 3.21% Y-o-Y
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Cipla Consolidated December 2019 Net Sales at Rs 4,371.00 crore, up 9.07% Y-o-Y
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Cipla share price rises as Nomura upgrades to buy
Nomura revised earnings estimate lower to 11 percent/8 percent/9 percent for FY21/21/22 on delay in provential launch.
Moneycontrol
Like
reply
Reply
@databot • Reputation: 2,050

Motilal Oswal target on CIPLA
Date: 06-Feb-20 Broker: Motilal Oswal Price @ Call: 446.8 Target: 490 Recommendation: NEUTRAL
Like
reply
Reply
@dreambig • Reputation: 2,020

Btst +positional
Buy cipla cash 440-430
Sl 424
Tgt 460/490/520/550++
Educational watch levels
Plz read disclaimer before any act
Like
reply
Reply (6)
Latest replies
DREAM BIG VIEW @dreambig
Feb 6 7:23 PM

Cipla
439 to 442.5
3+ points dn
Intra traders can book
Rest all tgt are positional
DREAM BIG VIEW @dreambig
Feb 7 3:39 PM

Btst cipla buy updates
437.2 to 444.9
7.5+ points dn Just 1 day holding
💸💸💸💸
Book as comforts
DREAM BIG VIEW @dreambig
Feb 10 3:38 PM

Positional cipla buy updates
437.2 to 451
13.5 points till
Near tgt1
💸💸💸💸💸
Book as comforts
DREAM BIG VIEW @dreambig
Feb 11 8:40 PM

Positional cipla buy updates
Given 06/02/2020
437.2 to 451.9
14.5+ points till
Near tgt1
💸💸💸💸💸
Book as comforts
DREAM BIG VIEW @dreambig
Feb 12 3:18 PM

Positional cipla buy updates
Given 06/02/2020
437.2 to 454.9
17.5+ points till
Near tgt1
💸💸💸💸💸
Book as comforts
@newsbot • Reputation: 2,308
Cipla sees recovery in emerging markets in Q4FY20, here are highlights of analyst call
The top 3 products of the US business contributed around 25-30 percent to the overall US revenues.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
What should investors do with Cipla post Q3: buy, sell or hold?
Revenue during the quarter grew 9.1 percent year-on-year to Rs 4,371 crore with India business showing a 13 percent growth and North America 11 percent.
Moneycontrol
Like
reply
Reply

RISKY WITH SMALL PROFIT, INTRADAY BUY CIPLA AT 449, SL 447, TARGET 453+++
Like
reply
Reply (2)
Latest replies

👆 CIPLA, READ WITH SMALL STOP LOSS

CIPLA SL GONE!!
@pyramidstock • Reputation: 2,460
Pyramidstock in CIPLA
buy cipla cmp 446-47 Sl 435 tgt 455-465-478 res...

463+ enjoy and book profit
Like
reply
Reply
@stocktrendr • Reputation: 319

Cipla: UBS Maintained ‘Buy’ with a price target of Rs 555.
Like
reply
Reply
@newsbot • Reputation: 2,308
Cipla rejigs India biz, integrates domestic, generics and consumer divisions
The company said the new structure will unlock synergies across portfolio, distribution and consumer-focused initiatives.
Moneycontrol
Like
reply
Reply
@ravikanthchopperla • Reputation: 11,889

Cipla company reported its Q3 FY20 results during market hours. Profit increased 5.7% y/y to Rs 351 crore, while revenue was up 9.1% to Rs 4,371 crore. EBITDA margin declined 30bps to 17.3%. The stock closed 0.2% lower.
Like
reply
Reply
@newsbot • Reputation: 2,308
XLRI completes final placement in two days, average salary up by Rs 2 lakh at Rs 24.3 lakh pa
The final recruitment process saw participation from 108 recruiters with 362 domestic and international offers.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Cipla Q3 profit rises 5.7% to Rs 351 cr, but operating margin contracts
Company said active pharmaceutical ingredient (API) business increased 6 percent YoY.
Moneycontrol
Like
reply
Reply
@ravikanthchopperla • Reputation: 11,889

BRIEF-India's Cipla Dec-Qtr Consol Net Profit Rises - Reuters
05-Feb-2020 03:22:31 PM
Feb 5 (Reuters) - Cipla Ltd CIPL.NS:
DEC QUARTER CONSOL NET PROFIT 3.51 BILLION RUPEES VERSUS PROFIT OF 3.32 BILLION RUPEES YEAR AGO
CONSENSUS FORECAST FOR DEC QUARTER CONSOL NET PROFIT WAS 4.2...
Read more...
Like
reply
Reply
@TTA • Reputation: 23,829
Cipla Q3 results: Profit inches up 6% to Rs 351 crore, misses projections
Analysts in an ET NOW poll had projected the number at Rs 431 crore.
The Economic Times
Like
reply
Reply
@pyramidstock • Reputation: 2,460
Pyramidstock in CIPLA
buy cipla cmp 446-47 Sl 435 tgt 455-465-478 res...

459 safe player book risky hold
Like
reply
Reply
@pyramidstock • Reputation: 2,460

buy cipla cmp 446-47 Sl 435 tgt 455-465-478 result today
Like
reply
Reply
@newsbot • Reputation: 2,308
Market Headstart: Nifty likely to reclaim 12,000; investors hope for more stimulus in China
Trends on SGX Nifty indicate a negative opening for the broader index in India, with a 20 points loss or 0.17 percent. The Nifty futures were trading around 11,952-level on the Singaporean Exchange.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
link
USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert
The USFDA today approved Ranbaxy’s drug called Plendil generic, which is used for hypertension. Ranbaxy was expected to be the authorised generic for this particular drug, but it is already genericised and there are already 6-7 players in this market for this particular drug.
Moneycontrol
Like
reply
Reply
@karthikk • Reputation: 32
Trade for you in CIPLA
Wait for good entry Chart for reference Join...

Broke the traingle and gone to the target of traingle
Like
reply
Reply
@HarmonicsTraders • Reputation: 1,306

Reversal day for CIPLA is Feb 3 based on Gann Maths method
Like
reply
Reply
CIPLA FEB20 FUT

Type
Sell
Instrument
CIPLA FEB20 FUT
Entry Price
₹449.4
Price@Trade
₹449.4
Target Price
₹350
Stop Price
₹500
Valid Till
Feb 27, 2020 3:20 PM
Margin
₹91,106.47 approx for 1150 Qty
Status
Exited
Exit Price
₹444.75
Net P&L
5.87% Profit
Like
reply
Reply (1)
Latest replies

Update
Exited
Exit Price
₹444.75
Net P&L
5.87% Profit
  • CIPLA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization42,645.7
    Enterprise Value42,471.14
    Price to Earnings29.77
    Price to Book Value2.7
    Return on Capital Employed0.13
    Return on Equity0.1
    Face Value2
    Dividend Yield0.01
  • CIPLA Share Price - Technicals

    keyboard_arrow_down
    CIPLA - 52 Week High₹586
    CIPLA - 52 Week Low₹389.55
  • CIPLA - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    6-Feb-20Motilal OswalNeutral490
    11-Dec-19Geojit Financial ServicesHold487
    7-Nov-19SharekhanBuy540
    6-Nov-19Prabhudas LilladherReduce439
    3-Oct-19EdelweissBuy500
    CIPLA Brokerage Price Target
  • CIPLA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Feb 20448448.8434.5435.75
    Feb 19437.8449.2437.4447.5
    Feb 18433437.65428.1436
    Feb 17444.5445.75430.1431.9
    Feb 14444448.9441.5447.1
  • CIPLA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹447.72
    30 Day Moving Average₹457.49
    50 Day Moving Average₹462.39
    100 Day Moving Average₹458.83
    200 Day Moving Average₹490.82
  • CIPLA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue11,39010,974.580.04
    Operating Profit2,1181,596.260.33
    Profit Before Tax1,9111,186.940.61
    Net Income1,469974.940.51
  • CIPLA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds15,78214,1140.12
    Total Liabilities2,6373,497-0.25
    Total Assets18,41917,6100.05
  • CIPLA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,1172,205.56-0.49
    Cash from Investing Activity-593-1,191.75-0.5
    Cash from Financing Activity-351-1,008.97-0.65
    Net Cash Flow1734.8434.74
  • CIPLA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.080.06
    Return on Equity0.10.08
    Return on Capital Employed0.130.09
  • CIPLA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.12
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.16
    3 Year CAGR Growth in Net Income0.24
    3 Yr CAGR Growth - Diluted EPS0.24
  • CIPLA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.39
    5 Year CAGR Growth in Operating ProfitNA
    5 Year CAGR Growth in EBIDTA0.05
    5 Year CAGR Growth in Net Income-0.03
    3 Yr CAGR Growth - Diluted EPS-0.03
  • CIPLA - Recent News

    keyboard_arrow_down
    NewsBot
    Feb 20 7:18 PM
    Gujarat Gas, Britannia among 10 stocks which brokerages have upgraded to 'buy'
    Moneycontrol
    NewsBot
    Feb 18 2:08 PM
    Hot Stocks: 'Use rally in PSU bank and auto stocks to create fresh shorts'
    Moneycontrol
    NewsBot
    Feb 18 2:03 PM
    Market Headstart: Nifty likely to consolidate further; avoid long positions for now
    Moneycontrol
    NewsBot
    Feb 15 12:58 AM
    Will the Wockhardt move help Dr Reddy's break into the big league?
    Moneycontrol
    NewsBot
    Feb 12 12:58 AM
    Indian drug companies get enquries on supplies of anti-HIV drugs for Coronavirus treatment
    Moneycontrol
    NewsBot
    Feb 11 8:58 PM
    Hold Cipla; target of Rs 490: ICICI Direct
    Moneycontrol
    NewsBot
    Feb 11 5:23 PM
    Cipla share price rises on distribution agreement for antipsychotic drug
    Moneycontrol
    NewsBot
    Feb 11 1:48 PM
    Stocks in the news: ITC, Cipla, Oil India, Petronet LNG, Kalpataru Power, Punjab & Sind Bank
    Moneycontrol
    NewsBot
    Feb 10 9:23 PM
    Buy Cipla target of Rs 540: Sharekhan
    Moneycontrol
    NewsBot
    Feb 10 1:23 PM
    Stocks in the news: ACC, M&M, Yes Bank, Tata Steel, Britannia, Cipla, Om Metals, MGL
    Moneycontrol
  • CIPLA - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Divi's Laboratories Ltd. Sector: Pha...
    Glenmark Pharmaceuticals Ltd. Sector...
    Strides Pharma Science Ltd. Sector: P...
    Apollo Hospitals Enterprise Ltd. Sec...
  • CIPLA - More Information

    keyboard_arrow_down

    Cipla Ltd:
    Cipla Limited, along with its multiple subsidiaries, is responsible for the manufacture and sale of pharmaceutical goods in India. It provides a variety of formulations and active pharmaceutical ingredients in various aspects like urology, ophthalmology, malaria, oncology, neurosciences, women’s and children’s health, hepatitis, critical care, osteoporosis, and infectious diseases.
    The company provides multiple inhalation therapy devices like nasal sprays, metered-dose inhalers, accessory devices, dry powder inhalers, and nebulizers. Apart from manufacturing and selling these products in India, it also exports to Russia, the Middle East, Asia, Australia, New Zealand, and Latin America and other regions internationally.
    On 17th of August in 1935, Cipla got registered as a public limited with a capital of Rs. 6 lakh and is a Mumbai based Company in India. During the Second World War, when the drug supplies were topped in 1941, the company started to produce fine chemicals. At this point, Cipla dedicated its facilities to provide a variety of ingenious drugs.
    About Company Information:
    Within the next two decades after the inception of the Second World War, in 1960, the company started its operations in Vikhroli, Mumbai. This was their second plant. At this unit, they produced fine chemicals related to natural products. Ampicillin was manufactured for the first time in the country in 1968 by Cipla. To cultivate medicinal plants, the company then started their Agricultural Research Division, located in Bangalore, in the year 1972.
    In 1982, the company started operating in its fourth manufacturing unit located in Patalganga, Maharashtra. The company collaborated with the National Chemical Laboratory in Pune, in the year 1984 to produce anti-cancer drugs like vincristine and vinblastine. Collaborating with Indian Institute of Chemical Technology, in 1991, a drug considered to be a breakthrough in chemotherapy, named etoposide was launched by the company. Later on, an antiretroviral drug called zidovudine was also manufactured by the company in association with Indian Institute of Chemical Technology.
    Nevirapine, an antiretroviral drug used to stop AIDS transmission in a child from a mother, was launched by the company in 1999. Cipla was the first company, outside of Europe and U.S.A, which began CFC-free-inhalers, in the year 2000. In February in 2007, the company allied with the Drugs for Neglected Diseases Initiative for developing a new anti-malarial drug. This was a worldwide initiative taken by the company with a non-profit organization like DNDI.
    In April of 2010, the company started its operations for commercial production of a variety of pharmaceutical formulations at their SEZ project in Indore, MP. On the 21st of July, 2012, Cipla revealed that they were to collaborate with DNDi (a non-profit R&D organization) for developing an improved form of antiretroviral (ARV) combo therapy which will specifically treat kids affected by HIV/AIDS.
    On the 17th of April, 2013, Cipla announced that they would be the first to launch a biosimilar of Etanercept in the country which will be targeted to treat rheumatic disorders. On the 20th of February in 2014, Cipla announced their alliance with MSD which would give them a non-exclusive license using which they would sell raltegravir 400mg tablet (a drug from MSD) along with marketing and distribution of the drug but down under a different brand name.
    In February 2015, Cipla revealed to have been awarded a Global Fund ARV Tender which is worth USD 188.95 million for developing antiretroviral drugs.
    On the 12th of October, 2016, Cipla announced the formal closing of US FDA inspection that was conducted in July-August in the year 2015. Cipla was given the establishment inspection report by the FDA, and it was held AT THE Indore Unit of the company. On the 30th of November, 2017, Cipla publicized the fact that the company had received approval from the World Health Organization (WHO) for a product name Q-TIB, which is essentially a combination of novel fixed-dose within a single tablet form. This was the first combination to ever exist in the world.
    How Cipla Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cipla Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cipla Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.